Evidence map›Paper›PMID 38816055›Full record

ArticleBMJ open2024

Propofol enhancement of slow wave sleep to target the nexus of geriatric depression and cognitive dysfunction: protocol for a phase I open label trial.

Rachel Lynn Rios, Michael Green, S Kendall Smith, MohammadMehdi Kafashan, ShiNung Ching, Nuri B Farber, Nan Lin, Brendan P Lucey, Charles F Reynolds, Eric J Lenze and 2 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04680910 (Precision Targeting of Propofol-induced Electroencephalographic Slow Waves), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04680910 phase1completednot on this map

Precision Targeting of Propofol-induced Electroencephalographic Slow Waves: a Novel Phase I Paradigm for Treatment-resistant Major Depressive Disorder

TypeinterventionalSponsorWashington University School of MedicineRan2021 to 2025Enrolled16ConditionsTreatment-resistant DepressionArmsPropofol, Electroencephalography (EEG), Slow-Wave Activity
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Pharmacotherapy of major depressive disorder in older adults: from an evidence-informed stepwise algorithm to precision medicine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rachel Lynn RiosDepartment of Anesthesiology, Washington University School of Medicine in St. Louis, St Louis, Missouri, USA.
Michael GreenDepartment of Anesthesiology, Washington University School of Medicine in St. Louis, St Louis, Missouri, USA.
S Kendall SmithDepartment of Anesthesiology, Washington University School of Medicine in St. Louis, St Louis, Missouri, USA.ORCID 0000-0003-0718-1150
MohammadMehdi KafashanDepartment of Anesthesiology, Washington University School of Medicine in St. Louis, St Louis, Missouri, USA.
ShiNung ChingDepartment of Electrical & Systems Engineering, Washington University in St. Louis, St Louis, Missouri, USA.
Nuri B FarberDepartment of Psychiatry, Washington University School of Medicine in St. Louis, St Louis, Missouri, USA.
Nan LinDepartment of Biostatistics and Data Science, Washington University in St Louis, St Louis, Missouri, USA.
Brendan P LuceyCenter on Biological Rhythms and Sleep, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Charles F ReynoldsDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Eric J LenzeDepartment of Anesthesiology, Washington University School of Medicine in St. Louis, St Louis, Missouri, USA.
Ben Julian Agustin PalancaDepartment of Anesthesiology, Washington University School of Medicine in St. Louis, St Louis, Missouri, USA palancab@wustl.edu.ORCID 0000-0001-7535-5701
SWIPED Study Team

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
PHARMacist and Community Health Support to Optimize Medications After Trauma Surgery (PHARM-C)P50MH122351 · NIMH · WASHINGTON UNIVERSITY · PI Eric J Lenze · 2021 to 2026
$10.8M
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) TrialU01MH128483 · NIMH · WASHINGTON UNIVERSITY · PI LENZE, ERIC J, PALANCA, BEN JULIAN · 2022 to 2025
$2.8M
Disruptions of Brain Networks and Sleep by Electroconvulsive TherapyK01MH128663 · NIMH · WASHINGTON UNIVERSITY · PI MohammadMehdi Kafashan · 2022 to 2026
$792k
Delirium, Acute Inflammation, and Rhythmic Transcriptomics (DART)R03AG082988 · NIA · WASHINGTON UNIVERSITY · PI SMITH, SARAH KENDALL · 2023 to 2023
$311k
NCATS NIH HHS UL1 TR002345NIA NIH HHS R03 AG082988NIMH NIH HHS K01 MH128663NIMH NIH HHS P50 MH122351NIMH NIH HHS U01 MH128483
6 · The paper itself

Abstract

introductionLate-life treatment-resistant depression (LL-TRD) is common and increases risk for accelerated ageing and cognitive decline. Impaired sleep is common in LL-TRD and is a risk factor for cognitive decline. Slow wave sleep (SWS) has been implicated in key processes including synaptic plasticity and memory. A deficiency in SWS may be a core component of depression pathophysiology. The anaesthetic propofol can induce electroencephalographic (EEG) slow waves that resemble SWS. Propofol may enhance SWS and oral antidepressant therapy, but relationships are unclear. We hypothesise that propofol infusions will enhance SWS and improve depression in older adults with LL-TRD. This hypothesis has been supported by a recent small case series. METHODS AND ANALYSIS: SWIPED (Slow Wave Induction by Propofol to Eliminate Depression) phase I is an ongoing open-label, single-arm trial that assesses the safety and feasibility of using propofol to enhance SWS in older adults with LL-TRD. The study is enrolling 15 English-speaking adults over age 60 with LL-TRD. Participants will receive two propofol infusions 2-6 days apart. Propofol infusions are individually titrated to maximise the expression of EEG slow waves. Preinfusion and postinfusion sleep architecture are evaluated through at-home overnight EEG recordings acquired using a wireless headband equipped with dry electrodes. Sleep EEG recordings are scored manually. Key EEG measures include sleep slow wave activity, SWS duration and delta sleep ratio. Longitudinal changes in depression, suicidality and anhedonia are assessed. Assessments are performed prior to the first infusion and up to 10 weeks after the second infusion. Cognitive ability is assessed at enrolment and approximately 3 weeks after the second infusion. ETHICS AND DISSEMINATION: The study was approved by the Washington University Human Research Protection Office. Recruitment began in November 2022. Dissemination plans include presentations at scientific conferences, peer-reviewed publications and mass media. Positive results will lead to a larger phase II randomised placebo-controlled trial. TRIAL REGISTRATION NUMBER: NCT04680910.

Indexed as

Cognitive DysfunctionPropofolSleep, Slow-WaveAgedAnesthetics, IntravenousClinical Trials, Phase I as TopicDepressive Disorder, Treatment-ResistantElectroencephalographyFemaleHumansMaleMiddle AgedAnesthetics, IntravenousPropofolAdult anaesthesiaCognitionDepression & mood disordersElectroencephalographyGERIATRIC MEDICINESleep medicine

Identifiers

PMID38816055
PMCPMC11138309

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.